BR0215855A - Compostos, enantiÈmeros, composição farmacêutica, uso de compostos e processo para a fabricação de compostos - Google Patents

Compostos, enantiÈmeros, composição farmacêutica, uso de compostos e processo para a fabricação de compostos

Info

Publication number
BR0215855A
BR0215855A BR0215855-8A BR0215855A BR0215855A BR 0215855 A BR0215855 A BR 0215855A BR 0215855 A BR0215855 A BR 0215855A BR 0215855 A BR0215855 A BR 0215855A
Authority
BR
Brazil
Prior art keywords
compounds
pro
compound
pharmaceutical composition
medicines
Prior art date
Application number
BR0215855-8A
Other languages
English (en)
Other versions
BRPI0215855B1 (pt
Inventor
Jan Wim Vrijbloed
Daniel Obrecht
John Anthony Robinson
Odile Sellier
Marc Kessler
Original Assignee
Universitot Zuerich
Polyphor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitot Zuerich, Polyphor Ltd filed Critical Universitot Zuerich
Publication of BR0215855A publication Critical patent/BR0215855A/pt
Publication of BRPI0215855B1 publication Critical patent/BRPI0215855B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

"COMPOSTOS, ENANTIÈMEROS, COMPOSIçãO FARMACêUTICA, USO DE COMPOSTOS E PROCESSO PARA A FABRICAçãO DE COMPOSTOS". Peptidomiméticos de <225>-hairpin fixados em matriz de fórmula geral (I) em que Z é uma cadeia fixada na matriz de 12 resíduos de <244>-aminoácido que, dependendo de suas posições na cadeia (contadas partindo do aminoácido N-terminal) são Gly, ou Pro, ou de certos tipos que, como os símbolos restantes na fórmula acima, são definidos na descrição e nas reivindicações, e sais dos mesmos, tem a propriedade de inibir seletivamente o crescimento de ou exterminar microorganismos como Pseudomonas aeruginosa e Acinetobacter. Eles podem ser usados como desinfetantes para alimentos, cosméticos, medicamentos e outros materiais contendo nutrientes, ou como medicamentos para tratar ou prevenir infecções. Em uma forma de realização específica, a matriz é baseada no D-Pro-L-Pro dipeptídeo. Estes peptidomiméticos <225>-hairpin podem ser fabricados pelos processos que são baseados em uma estratégia sintética de fase sólida e solução mista.
BRPI0215855A 2002-08-20 2002-08-20 peptídeos cíclicos ligados à matriz com ação antimicrobiana BRPI0215855B1 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/009278 WO2004018503A1 (en) 2002-08-20 2002-08-20 Template-fixed peptidomimetics with antibacterial activity

Publications (2)

Publication Number Publication Date
BR0215855A true BR0215855A (pt) 2005-07-12
BRPI0215855B1 BRPI0215855B1 (pt) 2016-12-13

Family

ID=31896807

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0215855A BRPI0215855B1 (pt) 2002-08-20 2002-08-20 peptídeos cíclicos ligados à matriz com ação antimicrobiana

Country Status (10)

Country Link
US (2) US7582604B2 (pt)
EP (1) EP1532164B1 (pt)
JP (1) JP4221368B2 (pt)
CN (1) CN1688600B (pt)
AR (1) AR043678A1 (pt)
AU (1) AU2002342618C1 (pt)
BR (1) BRPI0215855B1 (pt)
CA (1) CA2496215C (pt)
HK (1) HK1081561A1 (pt)
WO (1) WO2004018503A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096839A1 (en) * 2003-05-02 2004-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
DK1633774T3 (da) 2003-06-18 2010-05-25 Tranzyme Pharma Inc Makrocykliske motilinreceptorantagonister
CN105111280B (zh) * 2005-02-17 2020-01-24 波利弗尔有限公司 具有蛋白酶抑制活性的模板固定的β-发夹肽模拟物
KR101420198B1 (ko) * 2005-02-17 2014-08-13 폴리포 리미티드 프로테아제 저해 활성을 가지는 주형-고정된 β-헤어핀 구조의 펩티드모방체
WO2007079597A1 (en) * 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
US8633163B2 (en) * 2007-01-29 2014-01-21 Polyphor Ltd. Template-fixed peptidomimetics
AU2007348171B2 (en) 2007-02-28 2012-09-06 Polyphor Ltd. Template-fixed peptidomimetics
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US8895499B2 (en) 2010-08-05 2014-11-25 Polyphor Ag β-hairpin peptidomimetics
WO2013033645A1 (en) * 2011-08-31 2013-03-07 New York University Thioether-,ether-, and alkylamine-linked hydrogen bond surrogate pertidomimentics
WO2013050346A1 (en) * 2011-10-07 2013-04-11 Polyphor Ag Template -fixed peptidomimetics as inhibitors of fpr1
PL2882770T3 (pl) 2012-08-08 2018-01-31 Polyphor Ag Kombinacje z cyklicznym peptydem
SG11201507977UA (en) * 2013-03-30 2015-10-29 Polyphor Ag Beta-hairpin peptidomimetics
NZ712739A (en) * 2013-03-30 2021-07-30 Polyphor Ag Beta-hairpin peptidomimetics
WO2016050361A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
WO2016050360A1 (en) 2014-09-30 2016-04-07 Polyphor Ag Beta-hairpin peptidomimetics
CA2979437A1 (en) 2015-03-23 2016-09-29 Polyphor Ag Beta-hairpin peptidomimetics
JP6501615B2 (ja) 2015-05-27 2019-04-17 キヤノン株式会社 液体現像剤及び該液体現像剤の製造方法
US11629171B2 (en) 2017-11-10 2023-04-18 Spexis Ag Beta-hairpin peptidomimetics
WO2023227771A1 (en) 2022-05-27 2023-11-30 Fundación Privada Instituto De Salud Global Barcelona Cyclic peptides with antibacterial activity against multidrug resistant (mdr) pathogens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916872A (en) 1996-07-24 1999-06-29 Intrabiotics Pharmaceuticals, Inc. Cyclic peptides having broad spectrum antimicrobial activity
AU4905497A (en) 1996-10-11 1998-05-11 Pence, Inc. Antimicrobial peptide analogs of gramicidin s and compositions comprising them
AU5856699A (en) * 1999-08-30 2001-03-26 Polyphor Ag Synthesis of template-fixed beta-hairpin loop mimetics
US7253146B2 (en) * 2001-02-23 2007-08-07 Polyphor Ltd Template-fixed peptidomimetics with antimicrobial activity

Also Published As

Publication number Publication date
CA2496215C (en) 2013-07-16
CN1688600A (zh) 2005-10-26
EP1532164A1 (en) 2005-05-25
WO2004018503A1 (en) 2004-03-04
US7582604B2 (en) 2009-09-01
US20050239693A1 (en) 2005-10-27
CA2496215A1 (en) 2004-03-04
US20100056432A1 (en) 2010-03-04
HK1081561A1 (en) 2006-05-19
BRPI0215855B1 (pt) 2016-12-13
AR043678A1 (es) 2005-08-10
AU2002342618B2 (en) 2007-12-20
AU2002342618C1 (en) 2008-10-30
CN1688600B (zh) 2010-04-28
EP1532164B1 (en) 2012-09-26
JP2006513981A (ja) 2006-04-27
AU2002342618A1 (en) 2004-03-11
JP4221368B2 (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
BR0215855A (pt) Compostos, enantiÈmeros, composição farmacêutica, uso de compostos e processo para a fabricação de compostos
WO2007079605A3 (en) Template-fixed peptidomimetics with antimicrobial activity
WO2002070547A8 (en) Template-fixed peptidomimetics with antimicrobial activity
BRPI0410037B8 (pt) inibidores de fosfatidilinositol 3-cinase, sua composição farmacêutica, e seu uso
BR0213877A (pt) Compostos orgânicos
RU2011132893A (ru) Дезинфицирующее средство
ATE482616T1 (de) Zusammensetzungen mit hoher antiviraler und antibakterieller wirkung
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
BRPI0416283A (pt) compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
BR0210344A (pt) Inibidores da hiv protease, composições contendo os mesmos, seus usos farmacêuticos e materiais para a sua sìntese
BR9916732A (pt) Derivados de ácido malÈnico, processo para a sua preparação, seu uso e composições farmacêuticas contendo-os (inibição da atividade do fator xa)
BR0316091A (pt) Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
BR0108694A (pt) Derivados de ácido malÈnico, processo para preparação dos mesmos, uso dos mesmos como inibidor de atividade do fator xa e composições farmacêuticas que contêm os mesmos
TW200733878A (en) Polyalkoxylate-comprising solid plant protection compositions, processes for their preparation and their use
BRPI0520016A2 (pt) compostos, enanciÈmeros, composição farmacêutica, uso de compostos, processo para a fabricação de compostos, e, modificação dos processos
BR112015024939A2 (pt) composto, diastereoisômero ou epímero de um composto, composição farmacêutica, uso de um composto, processo para a preparação de um composto, e, método para tratamento de uma infecção
BR0117190A (pt) Composto, composição farmacêutica, uso do composto, e, processo para fabricá-lo
BRPI0702299B1 (pt) composição microbicida
WO2007006521A3 (en) Nutritional mixtures with a high and increased efficacy
BRPI0607918A2 (pt) tetraidro-piridoazepin-8-onas e compostos relacionados para o tratemento da esquizofrenia.
BRPI0500149A (pt) Composições de germicidas contendo misturas de ftalaldeìdo e métodos de uso de tais composições para desinfecção ou esterilização
BRPI0512951A (pt) compostos, processo para sua fabricação, composições farmacêuticas contendo os mesmos, uso e método para tratamento e/ou prevenção de doenças que são moduladas pelos agonistas de ppar(delta) e/ou ppar(alpha)
BRPI0409881A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0311760A (pt) Composto, pró-droga de um composto, processo para a preparação do composto, composições farmacêuticas que compreendem o mesmo, sua utilização e método de tratamento de diabetes do tipo 2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2595 DE 29-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.